Miragen Therapeutics, Inc. (MGEN): Price and Financial Metrics


Miragen Therapeutics, Inc. (MGEN): $23.01

-0.02 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MGEN Stock Price Chart Interactive Chart >

Price chart for MGEN

MGEN Price/Volume Stats

Current price $23.01 52-week high $34.05
Prev. close $23.03 52-week low $4.66
Day low $22.97 Volume 44,300
Day high $23.90 Avg. volume 134,027
50-day MA $18.20 Dividend yield N/A
200-day MA $14.23 Market Cap 89.92M

Miragen Therapeutics, Inc. (MGEN) Company Bio


Miragen Therapeutics, Inc., a clinical stage biopharmaceutical company, develops microRNA-targeted therapies for various unmet medical needs. It focuses on various therapeutic areas, such as cancer, pathologic fibrosis, neuro-inflammatory, and cardiovascular diseases. The company was founded in 2006 and is based in Boulder, Colorado.


MGEN Latest News Stream


Event/Time News Detail
Loading, please wait...

MGEN Latest Social Stream


Loading social stream, please wait...

View Full MGEN Social Stream

Latest MGEN News From Around the Web

Below are the latest news stories about Miragen Therapeutics Inc that investors may wish to consider to help them evaluate MGEN as an investment opportunity.

miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical OfficerViridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye diseaseCompany recently licensed exclusive rights from Xencor, Inc. to develop and commercialize therapeutic antibodies targeting IGF-1R incorporating Xtend™ Fc half-life extension technology BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”). Beginning tomorrow, Viridian will trade on NASDAQ under the ticker symbol "VRDN" and its common stock will trade under a new CUSIP number, 92790C104. The Company also announced to...

Yahoo | January 19, 2021

Oppenheimer: These 3 Stocks Could Spike Over 80%

Wall Street’s best firms don’t just look at the stocks, they look at the big picture, too. And Oppenheimer’s chief investment strategist, John Stoltzfus, is particularly adept at showing us the macro view. In his first note of the new year, Stoltzfus notes a series of factors that are going to impact the markets. The big news, of course, the 800-pound gorilla that cannot be ignored, is the ongoing COVID epidemic. The disease is coming back strong now that we’re well into winter – which was somewhat expected, as it’s typical behavior for flu-like respiratory viruses.

Michael Marcus on TipRanks | January 8, 2021

61 Biggest Movers From Yesterday - Stocks News Feed

Gainers Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 48.4% to close at $6.09 on Tuesday amid strength in Bitcoin prices. Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares jumped 40.3% to close at $1.81 on Tuesday as the company disclosed that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints. Miragen Therapeutics, Inc. (NASDAQ:… Read More »61 Biggest Movers From Yesterday

Stocks News Feed | November 18, 2020

MiRagen reports loss, effects reverse stock split

MiRagen Therapeutics Inc. (Nasdaq: MGEN), a Boulder-based biotechnology company developing new treatments for patients with diseases that are underserved by current therapies, reported a net loss o…

Broomfield Enterprise | November 12, 2020

miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

* Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) * Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline * After completion of the acquisition of Viridian Therapeutics and the private placement financing, miRagen has cash on hand of approximately $144 million and estimated cash runway through 2023 * Announces 1-for-15 reverse stock split to be effective as of November 12, 2020 and trading of the common stock will begin on a split-adjusted basis when markets open on November 13, 2020BOULDER, Colo...

Yahoo | November 10, 2020

Read More 'MGEN' Stories Here

MGEN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -36.87%
5-year -85.47%
YTD N/A
2021 0.00%
2020 128.52%
2019 -84.16%
2018 -70.95%
2017 108.18%

Continue Researching MGEN

Want to see what other sources are saying about Miragen Therapeutics Inc's financials and stock price? Try the links below:

Miragen Therapeutics Inc (MGEN) Stock Price | Nasdaq
Miragen Therapeutics Inc (MGEN) Stock Quote, History and News - Yahoo Finance
Miragen Therapeutics Inc (MGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7536 seconds.